<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management - adults | Management | Diabetes - type 1 | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the primary care management of adults with type 1 diabetes."/><meta data-react-helmet="true" property="og:description" content="Covers the primary care management of adults with type 1 diabetes."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/diabetes-type-1/management/management-adults/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management - adults | Management | Diabetes - type 1 | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/diabetes-type-1/management/management-adults/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Diabetes - type 1</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management - adults</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/diabetes-type-1/","name":"Diabetes - type 1"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/diabetes-type-1/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management - adults"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Diabetes - type 1: </span><span>Scenario: Management of adults with type 1 diabetes</span></h1><p class="page-header__lead"><span>Last revised in November 2020</span></p></div><p class="visually-hidden">Covers the primary care management of adults with type 1 diabetes.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Diabetes - type 1 chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - adults"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - adults</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - children and young people"><a aria-current="false" href="../management-children-young-people/index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - children and young people</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#initial-care-support">Initial care and support</a><ol aria-label="Sections within Initial care and support" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#individual-care-plan">Individual care plan</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-f4d">Basis for recommendation</a></li></ol></li><li><a href="index.html#insulin-therapy">Insulin therapy</a></li><li><a href="index.html#target-hba1c">Target HbA1c</a><ol aria-label="Sections within Target HbA1c" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-313">Basis for recommendation</a></li></ol></li><li><a href="index.html#self-monitoring-of-blood-glucose">Self-monitoring of blood glucose</a><ol aria-label="Sections within Self-monitoring of blood glucose" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#target-glucose-self-monitoring-levels">Target glucose self-monitoring levels</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4dd">Basis for recommendation</a></li></ol></li><li><a href="index.html#lifestyle-management">Lifestyle management</a><ol aria-label="Sections within Lifestyle management" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#diet">Diet</a></li><li class=""><a href="index.html#alcohol-intake">Alcohol intake</a></li><li class=""><a href="index.html#exercise-physical-activity">Exercise and physical activity</a></li><li class=""><a href="index.html#smoking-substance-misuse">Smoking and substance misuse</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-14b">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-hypoglycaemia">Managing hypoglycaemia</a></li><li><a href="index.html#managing-diabetic-ketoacidosis">Managing diabetic ketoacidosis</a><ol aria-label="Sections within Managing diabetic ketoacidosis" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-1e3">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-intercurrent-illness">Managing intercurrent illness</a><ol aria-label="Sections within Managing intercurrent illness" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#sick-day-rules">&#x27;Sick-day rules&#x27;</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-a04">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-cardiovascular-risk">Managing cardiovascular risk</a><ol aria-label="Sections within Managing cardiovascular risk" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#antihypertensive-treatment">Antihypertensive treatment</a></li><li class=""><a href="index.html#lipid-modification">Lipid modification</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-1a7">Basis for recommendation</a></li></ol></li><li><a href="index.html#monitoring-for-complications">Monitoring for complications</a><ol aria-label="Sections within Monitoring for complications" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#eye-disease">Eye disease</a></li><li class=""><a href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a></li><li class=""><a href="index.html#neuropathy">Neuropathy</a></li><li class=""><a href="index.html#foot-problems">Foot problems</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-6fa">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management-adults" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management-adults" class="visually-hidden">Scenario: Management of adults with type 1 diabetes</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4d2e59ab-af47-450b-ab98-0616b8867968 --><!-- begin field 73a74864-58ba-401d-bcba-acd900ad872f --><p>From age 18 years onwards.</p><!-- end field 73a74864-58ba-401d-bcba-acd900ad872f --><!-- end item 4d2e59ab-af47-450b-ab98-0616b8867968 --></div><section aria-labelledby="initial-care-support" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-care-support">What initial care and support should I offer an adult with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8f452256-ab9c-486e-b46a-740fe5628975 --><!-- begin field 06f4236e-625b-428f-bab4-840c2f4a2f9d --><ul><li><strong>Ensure that an </strong><strong><a class="topic-reference internal-reference" href="index.html#individual-care-plan">individual care plan</a> is set up for the person by the diabetes specialist team.</strong><ul><li>After the initial plan is agreed, put arrangements in place to implement it without inappropriate delay. Arrange a review to reassess the person in the following weeks.  </li><li>Review the plan annually and modify it if necessary, taking into account changes in the person's wishes, circumstances, and clinical findings, and record the details. </li></ul></li><li><strong>Offer a structured education programme of proven benefit, for example the <a href="https://dafne.nhs.uk/" data-hyperlink-id="471ba73f-d6a0-46c2-89c2-a931009cc975">DAFNE</a> (dose-adjustment for normal eating) programme. </strong><ul><li>Offer this programme 6–12 months after diagnosis or at any time that is clinically appropriate and suitable for the person, regardless of duration of type 1 diabetes. </li><li>Explain to the person and/or their family/carers that structured education is an integral part of diabetes care.</li><li>For people who are unable or unwilling to participate in group education, provide an alternative of equal standard. </li></ul></li><li><strong>Provide information on:</strong><ul><li>The means and frequency of communicating with the diabetes specialist team. Ensure that the person and/or their family/carers know how to contact the diabetes team during working hours and out of hours, as available.</li><li>Government disability benefits — <a href="https://www.gov.uk/benefits-calculators" data-hyperlink-id="81db6aad-85ff-4438-b2c4-a931009cca11">Benefits calculators</a> are available at <a href="https://www.gov.uk/" data-hyperlink-id="7e929a84-f3fb-496f-b1bd-abc800545fea">www.gov.uk</a>.</li></ul></li><li><strong>Manage lifestyle issues, </strong><strong>such as diet, exercise, and alcohol intake.</strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#lifestyle-management">Lifestyle management</a> for more information.</li></ul></li><li><strong>Provide up-to-date information on diabetes support groups</strong> <strong>(local and national), including information on how to contact them and the benefits of membership. </strong><ul><li>For example, the Diabetes UK website (<a href="https://www.diabetes.org.uk/" data-hyperlink-id="55629234-95e2-4f9c-9d8b-abc800536bbf">www.diabetes.org.uk</a>) has information on <a href="https://www.diabetes.org.uk/guide-to-diabetes" data-hyperlink-id="24c6271b-4960-4266-b8b9-abc800536bda">Living with diabetes</a> and a <a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/How_we_help/Talk-to-someone/Careline/" data-hyperlink-id="ac1af5be-5314-4e40-a1c6-a931009cca2c">support helpline</a> for people with diabetes and their family/carers.</li><li>Provide this information at the time of diagnosis and periodically thereafter. Written information should also be available from the diabetes team.</li></ul></li></ul><!-- end field 06f4236e-625b-428f-bab4-840c2f4a2f9d --><!-- end item 8f452256-ab9c-486e-b46a-740fe5628975 --></div><section aria-labelledby="individual-care-plan" class="ChapterBody-module--wrapper--2HCfk "><h4 id="individual-care-plan">Individual care plan</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f3fcaac2-1a9a-4c32-bb5a-809e06e7e015 --><!-- begin field 63791476-fad2-4746-98dd-441238eba118 --><ul><li><strong>At the time of diagnosis, the diabetes specialist team should develop with (and explain to) all adults with type 1 diabetes a plan for their early care. </strong>To agree such a plan will generally require: <ul><li>Medical assessment to: <ul><li>Confirm diagnosis of type 1 diabetes. </li><li>Ensure appropriate acute care is given when needed.</li><li>Review and detect potentially confounding diseases and drugs.</li><li>Detect adverse vascular risk factors, such as hypertension.</li></ul></li><li>Environmental assessment to understand: <ul><li>The social, home, work, and recreational circumstances of the person and carers. </li><li>The person's preferences in nutrition and physical activity. </li><li>Other relevant factors, such as substance use. </li></ul></li><li>Cultural and educational assessment to identify prior knowledge and to enable optimal advice and planning on: <ul><li>Treatment modalities.</li><li>Diabetes education programmes.</li></ul></li><li>Assessment of emotional state to determine the appropriate pace of education. </li></ul></li><li><strong>The initial diabetes assessment will include a general examination and a review of the following:</strong><ul><li>Acute medical history.</li><li>Social, cultural, and educational history/lifestyle review.</li><li>Complications history/symptoms.</li><li>Long-term/recent diabetes history.</li><li>Other medical history/systems.</li><li>Family history of diabetes/cardiovascular disease.</li><li>Medication history/current medicines.</li><li>Vascular risk factors.</li><li>Smoking status, general examination, weight/body mass index.</li><li>Foot/eye/vision examination.</li><li>Urine albumin excretion/urine protein/serum creatinine.</li><li>Psychological wellbeing.</li><li>Attitudes to medicine and self-care.</li><li>Immediate family and social relationships and availability of informal support. </li></ul></li><li><strong>The results of the assessment should be used to agree an individual and culturally appropriate care plan for the person with type 1 diabetes, which should include aspects of the following:</strong><ul><li>Diabetes education (sites and timescales of diabetes education and nutritional advice).</li><li>Insulin therapy (insulin injections, regimens, and dose adjustment).</li><li>Self-monitoring of blood glucose.</li><li>Treatment targets.</li><li>Hypoglycaemia (symptoms, risks, and treatment).</li><li>Management of special situations (for example driving, fasting, and physical activity).</li><li>Management of diabetes during a period of illness.</li><li>Cardiovascular risk factors (monitoring and management).</li><li>Complications (monitoring and management).</li><li>Means and frequency of communicating with the diabetes specialist team.</li><li>Frequency and content of follow-up consultations, including review of HbA1c levels and experience of hypoglycaemia, and next annual review.</li><li>Contraception and pregnancy planning advice (when appropriate).</li></ul></li></ul><!-- end field 63791476-fad2-4746-98dd-441238eba118 --><!-- end item f3fcaac2-1a9a-4c32-bb5a-809e06e7e015 --></div></section><section aria-labelledby="basis-for-recommendation-f4d" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-f4d">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f4df430e-8427-4e4a-9653-8e76b6d3bfee --><!-- begin field f4bf037d-2bc9-4cdd-ad72-692e0c2b045e --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng17/evidence/full-guideline-pdf-435400241" data-hyperlink-id="0da19505-b35e-4c8a-9c90-a93100987082">full NICE guideline</a>.</p><h5>Individual care plan</h5><ul><li>In the expert opinion of the NICE guideline development group (GDG), the time following diagnosis with type 1 diabetes is one of great stress for many people and management decisions taken at this time may have a long-term impact on the person. In order to be effective, these decisions need an assessment of medical and lifestyle factors that can be expected to affect various areas of diabetes management, including choice of treatment, monitoring requirements, and educational requirements.</li></ul><h5>Offering a structured education programme</h5><ul><li>The NICE GDG was aware that in people with chronic diseases, such as type 1 diabetes, education programmes have been shown to improve knowledge and disease management. <ul><li>The GDG searched for randomized trials comparing structured educational programmes with other educational programmes or usual care/no treatment in adults with type 1 diabetes. <ul><li>Overall, they were interested in HbA1c as an objective measure of continuing glucose control, and improvements in quality of life. Other outcomes considered were hypoglycaemia, hospital admissions, hypoglycaemia unawareness, adverse events, knowledge, and adherence to treatment.</li><li>Low- to very low-quality evidence showed a benefit for structured educational programmes compared with other educational programmes or usual care/no treatment.</li><li>Although the results across the range of educational programmes studied were not as positive as expected, the results of the DAFNE (dose-adjustment for normal eating) programme were superior to others. Since DAFNE is already widely used in the UK, it was considered to be the educational programme of choice.</li></ul></li><li>The GDG debated whether their recommendation should specify that DAFNE alone should be used. <ul><li>Considering that there are other educational programmes that appear to be useful but have not been formally studied, the GDG decided that they should stipulate that structured educational programmes had to fulfil the criteria of the <a href="https://www.nice.org.uk/guidance/qs6/chapter/Quality-statement-3-Structured-education-programmes-for-adults-with-type-1-diabetes" data-hyperlink-id="055d5a1d-6a1d-42a5-ac14-a9310098713d">NICE quality standards</a>.</li></ul></li><li>The GDG also discussed how soon after diagnosis the programme should be offered.<ul><li>It was agreed that the programme should be undertaken when the person with diabetes feels ready to engage fully, but the consensus was that for most people it would be worthwhile enrolling in DAFNE (or a similar programme) from a time point of 6–12 months after diagnosis since the first few months post-diagnosis are a period of considerable adjustment. The GDG thought that trying intensive education at this stage would be less worthwhile and even counterproductive. </li></ul></li></ul></li></ul><h5>Providing information on government disability benefits</h5><ul><li>CKS has extrapolated this recommendation from the NICE guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>] as the information is also relevant to adults with type 1 diabetes and their family/carers.</li></ul><h5>Managing lifestyle issues</h5><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#lifestyle-management">Lifestyle management</a> for more information.</li></ul><h5>Providing information on support groups</h5><ul><li>In the expert opinion of the NICE GDG, having type 1 diabetes can have a major impact on lifestyle and self-esteem and it would appear that support groups could have a role in providing for some needs outside the professional environment and even separately from immediate carers.</li><li>The NICE GDG reviewed the Diabetes Attitudes, Wishes and Needs (DAWN) questionnaire study, which highlighted that emotional support, along with family support, was a key factor in how well people with diabetes manage their condition. Support networks were considered at least as important as pharmacological treatment. </li><li>There is also some evidence that people who do not have access to a community of support, especially the young or elderly living alone, may be less likely to be compliant with their treatment regimen, thereby putting them at risk of inadequate control of their diabetes.</li></ul><!-- end field f4bf037d-2bc9-4cdd-ad72-692e0c2b045e --><!-- end item f4df430e-8427-4e4a-9653-8e76b6d3bfee --></div></section></section><section aria-labelledby="insulin-therapy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="insulin-therapy">Insulin therapy for adults with type 1 diabetes</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4cfb7aa8-e46d-4760-944f-a5fba483b606 --><!-- begin field 63e80eb6-2c76-469b-92be-f640b908c7d7 --><ul><li><strong>Insulin therapy should only be initiated and managed by healthcare professionals with the relevant expertise and training. </strong></li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for detailed information on insulin therapy, including available insulin preparations, recommended regimens, information on injection technique and injection sites, storage of insulin, adverse effects, safety issues, and general information on lifestyle and cultural aspects of insulin treatment (such as driving whilst on insulin treatment, fasting, shift work, holiday and travel, and insurance).</li></ul><!-- end field 63e80eb6-2c76-469b-92be-f640b908c7d7 --><!-- end item 4cfb7aa8-e46d-4760-944f-a5fba483b606 --></div></section><section aria-labelledby="target-hba1c" class="ChapterBody-module--wrapper--2HCfk "><h3 id="target-hba1c">What is the target HbA1c for adults with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cb8ecde8-7585-418c-b14c-e98df146a4b6 --><!-- begin field b6edb85e-4303-4cc5-8acd-81ac78f76f6a --><ul><li><strong>Support adults with type 1 diabetes to aim for a target HbA1c level of 48 mmol/mol (6.5%) or lower, to minimize the risk of long-term vascular <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a>.</strong><ul><li>For people with type 1 diabetes and chronic kidney disease not treated with dialysis, aim for a target HbA1C of less than 6.5% to less than 8%.   </li><li>Agree an individualized HbA1c target with the person, taking into account factors such as their daily activities, aspirations, likelihood of complications, comorbidities, occupation, and history of hypoglycaemia (blood glucose levels less than 3.5 mmol/L).</li><li>Ensure that aiming for an HbA1c target is not accompanied by problematic hypoglycaemia.</li></ul></li><li><strong>Measure HbA1c levels every 3–6 months in most people. </strong><ul><li>Consider measuring HbA1c levels more often if the person's blood glucose control is suspected to be changing rapidly, for example if the HbA1c level has risen unexpectedly above a previously sustained target.</li><li>Inform the person of their results after each measurement, and ensure that their most recent result is available at the time of consultation.</li></ul></li></ul><!-- end field b6edb85e-4303-4cc5-8acd-81ac78f76f6a --><!-- end item cb8ecde8-7585-418c-b14c-e98df146a4b6 --></div><section aria-labelledby="basis-for-recommendation-313" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-313">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3130dcaf-7062-4414-9869-d4b172250b45 --><!-- begin field 697240f7-a423-4866-9999-bd7eec2f8ee1 --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng17/evidence/full-guideline-pdf-435400241" data-hyperlink-id="0da19505-b35e-4c8a-9c90-a93100987082">full NICE guideline</a>.</p><h5>Measuring HbA1c</h5><ul><li><p>HbA1c (glycated haemoglobin) develops when haemoglobin joins with glucose in the blood, becoming ‘glycated’. By measuring HbA1c, healthcare professionals can get an overall picture of what a person's average blood glucose levels have been over 2–3 months. The higher the HbA1c, the greater the risk of developing diabetes-related complications [<a class="bibliography-reference internal-reference" href="../../references/index.html">WHO, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Diabetes.co.uk, 2019</a>].</p></li></ul><h5>Optimal HbA1c targets</h5><ul><li>Overall, low-quality evidence identified by NICE showed that lowering the HbA1c towards the non-diabetic range with intensified insulin therapy reduced the risk of microvascular and macrovascular complications. However, it also showed that attainment of lower HbA1c levels was associated with a greater risk of severe hypoglycaemia (hypoglycaemia event requiring help from a third party for correction). NICE, therefore, advises that targets for blood glucose control should take into account the person's ability to achieve them without increasing the risk of severe hypoglycaemia.</li><li>In deciding on the optimum HbA1c targets for adults with type 1 diabetes, the NICE guideline development group (GDG) considered that people should achieve a target that minimized their risk of developing complications from glycaemia. Since retinopathy is often the first microvascular complication to develop from inadequate blood glucose control, the GDG paid particular attention to the risk of developing this complication at varying blood glucose levels as reported by the Diabetes Control and Complications Trial (DCCT), a large randomized controlled trial (RCT) that compared the outcomes of intensive therapy with conventional therapy in people with type 1 diabetes.</li><li>The GDG decided on an HbA1c target of 48 mmol/mol (6.5%) on the grounds that a minimal risk of retinopathy was achieved at this level, with further improvements in HbA1c not achieving any further significant reduction in retinopathy risk. </li><li>The GDG recognized that such tight blood glucose control may not be desired by some people (for example people who drive for a living). In this case, an individualized HbA1c target should be agreed with the person.</li><li>The recommended HbA1c target range for people with diabetes and chronic kidney disease is based on the Kidney Disease: Improving Global Outcomes (KDIGO) <em>Clinical practice guideline for diabetes management in chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2020</a>]. </li></ul><h5>Frequency of HbA1c measurement</h5><ul><li>Very low-quality evidence identified by NICE showed that a knowledge of HbA1c at clinic appointments led to improvements in clinical outcomes; however, no data were available on the optimal frequency of HbA1c monitoring.</li><li>Owing to the lack of evidence and the fact that patient members of the GDG expressed concern that increasing the frequency of HbA1c monitoring may result in difficulties making arrangements to attend appointments, especially if a visit to a healthcare professional was required for a blood test in the week before a clinic appointment, the NICE GDG decided to retain the previous recommendation of 3–6 monthly monitoring, advising that an increase in the frequency may be considered if necessary (for example if the person's treatment regimen is altered).</li></ul><!-- end field 697240f7-a423-4866-9999-bd7eec2f8ee1 --><!-- end item 3130dcaf-7062-4414-9869-d4b172250b45 --></div></section></section><section aria-labelledby="self-monitoring-of-blood-glucose" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-monitoring-of-blood-glucose">What should I advise on self-monitoring of blood glucose?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8ed21e75-67bd-4f7e-996e-abe6013cb21d --><!-- begin field 2d9164d9-6a59-462e-bdf7-abe6013cb287 --><ul><li><strong>Self-monitoring of blood glucose refers to home blood glucose testing for people with diabetes to determine the amount of glucose in the blood at any given time. </strong><ul><li>To self-monitor, the person would need a blood glucose monitor, lancets (which fit into a finger-pricking device), and testing strips (on which the blood is collected for testing in the machine).</li><li>See the section on <a class="topic-reference internal-reference" href="index.html#target-glucose-self-monitoring-levels">Target glucose self-monitoring levels</a> for information on blood glucose self-monitoring target levels.</li></ul></li><li><strong>Self-monitoring skills should be taught at the time of diagnosis and at the time of initiation of insulin therapy, and should be reviewed at least annually. </strong>The review should include checking that the person knows:<ul><li>How to use their blood glucose monitoring meter — this can be done by asking them to demonstrate their technique.</li><li>When to test — for example before breakfast and 2 hours after meals, during periods of illness, before driving, and if they feel hypoglycaemic. </li><li>How to assess and respond to test results, including how to:<ul><li>Interpret trends in blood glucose levels as well as individual readings — this is important for adjusting insulin doses.</li><li>Identify the causes of high and low blood glucose values.</li></ul></li></ul></li><li><strong>Continuous glucose monitoring is a way of measuring glucose levels continuously throughout the day and night via a tiny electrode inserted under the skin. </strong><ul><li>Continuous glucose monitoring systems provide continuous measurements (every 1–5 minutes) of glucose concentrations in the interstitial fluid, which correlate with blood glucose levels. It can provide both retrospective and real-time information to detect hypoglycaemic and hyperglycaemic episodes, predict impending hypoglycaemia, and detect wide fluctuations in glucose levels (glycaemic variability).</li><li>Continuous glucose monitoring is not routinely recommended for adults with type 1 diabetes but may be considered in <a class="topic-reference internal-reference" href="index.html#target-glucose-self-monitoring-levels">certain circumstances</a>, for example in adults with more than 1 episode a year of severe hypoglycaemia with no obvious cause.</li></ul></li></ul><!-- end field 2d9164d9-6a59-462e-bdf7-abe6013cb287 --><!-- end item 8ed21e75-67bd-4f7e-996e-abe6013cb21d --></div><section aria-labelledby="target-glucose-self-monitoring-levels" class="ChapterBody-module--wrapper--2HCfk "><h4 id="target-glucose-self-monitoring-levels">What are the target glucose self-monitoring levels for adults with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e7bfaa81-727d-4535-8a04-abe900b3f6b9 --><!-- begin field 52f46cc1-7a55-4809-8332-abe900b3f709 --><ul><li><strong>Advise routine <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">self-monitoring of blood glucose</a> levels at least 4 times a day (including before meals and before bed). </strong><ul><li>More frequent monitoring (up to 10 times a day or more) may be required if any of the following apply: <ul><li>The <a class="topic-reference internal-reference" href="index.html#target-hba1c">target HbA1c&nbsp;level</a> is not achieved. </li><li>The frequency of hypoglycaemic episodes increases. </li><li>There is a legal requirement to do so, such as before driving. </li><li>During <a class="topic-reference internal-reference" href="index.html#managing-intercurrent-illness">periods of illness</a>.</li><li>Before, during, and after<strong><em> </em></strong>sport.</li><li>When planning a pregnancy, during pregnancy, and while breastfeeding. See the National Institute for Health and Care Excellence (NICE) guideline on <a data-hyperlink-id="7b5c7376-383d-4468-9fa8-a93100987b6c" href="https://www.nice.org.uk/guidance/ng3">Diabetes in pregnancy</a> for more information.</li><li>If there is a need to know blood glucose levels more than 4 times a day for other reasons, for example in people with impaired awareness of hypoglycaemia. See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#impaired-awareness-of-hypoglycaemia">Impaired awareness of hypoglycaemia</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for more information.</li><li>If it is necessary because of the person’s lifestyle, for example they drive for a long period of time, undertake a high-risk activity or occupation, or travel frequently or across time zones.</li></ul></li></ul></li><li><strong>Discuss optimal targets for glucose self-monitoring.</strong><ul><li><strong>The optimal targets for glucose self-monitoring in adults with type 1 diabetes are: </strong><ul><li>Fasting plasma glucose level of 5–7 mmol/L on waking.</li><li>Plasma glucose level of 4–7 mmol/L before meals at other times of the day.</li><li>For adults who choose to test after meals, plasma glucose level of 5–9 mmol/L at least 90 minutes after eating. </li></ul></li><li><strong>Agree bedtime target plasma glucose levels with the person. This should:</strong><ul><li>Take into account the timing of the last meal and its related insulin dose.</li><li>Be consistent with the recommended fasting level on waking.</li></ul></li><li><strong>Remind the person of the need to be particularly careful to avoid hypoglycaemia when driving.</strong> See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#driving">Driving</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for more information.</li></ul></li><li><strong><a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">Continuous glucose monitoring</a> is not routinely recommended for adults with type 1 diabetes. </strong><ul><li>The National Institute for Health and Care Excellence (NICE) recommends that real-time continuous glucose monitoring may be considered for adults with one or more of the following:<ul><li>Extreme fear of hypoglycaemia. </li><li>More than 1 episode a year of severe hypoglycaemia with no obvious cause.</li><li>Complete loss of awareness of hypoglycaemia.</li><li>Persistent hyperglycaemia (HbA1c of 75 mmol/mol or higher) despite testing at least 10 times a day.</li><li>Frequent (more than 2 episodes) of asymptomatic hypoglycaemia.</li></ul></li><li>The person must be willing to commit to using it at least 70% of the time and to calibrate it as needed.</li></ul></li></ul><!-- end field 52f46cc1-7a55-4809-8332-abe900b3f709 --><!-- end item e7bfaa81-727d-4535-8a04-abe900b3f6b9 --></div></section><section aria-labelledby="basis-for-recommendation-4dd" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4dd">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4dd37b4f-6d39-452a-8eb5-abe6013cb289 --><!-- begin field 7e2bc67e-5bc5-45f2-9f55-abe6013cb289 --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng17/evidence/full-guideline-pdf-435400241" data-hyperlink-id="0da19505-b35e-4c8a-9c90-a93100987082">full NICE guideline</a>.</p><h5>Routine self-monitoring of blood glucose</h5><ul><li>In the expert opinion of the NICE guideline development group (GDG), self-monitoring of blood glucose is central to the self-management of type 1 diabetes as strict blood glucose control has been shown to reduce the development and progression of long-term complications in people with diabetes.</li></ul><h5>Frequency of self-monitoring of blood glucose</h5><ul><li>NICE identified evidence (from randomized controlled trials [RCTs], a large cross-sectional study, a large case-series, and a small cross-over clinical trial) which showed that:<ul><li>People who monitored blood glucose had improved glucose control compared with people who did not monitor blood glucose levels at all.</li><li>Increased blood glucose monitoring (up to 4 times a day) was associated with substantial improvements in blood glucose control.</li><li>Increased frequency of blood glucose monitoring (more than 4 times a day) was associated with further improvements in blood glucose control, with testing up to 10 times a day associated with an improvement in HbA1c. However, the increments in the clinical benefits gained were smaller with higher frequencies of blood glucose testing.</li><li>From the evidence for routine testing, the GDG did not consider a test frequency of more than 8 times a day to be associated with clinically significant further improvement in glucose control. The GDG advised that the indication for people wishing (or needing) to test at greater frequency should be discussed with the person and they should be supported if extra tests are needed to accommodate lifestyle issues.</li><li>The GDG also recognized that there would be times when people with type 1 diabates might want to test blood glucose levels more frequently, for example before exercise, during periods of illness, and when considering pregnancy, and advises that they should be encouraged to increase their frequency of testing to avoid adverse outcomes.</li><li>Overall, no adverse outcomes were reported from an increased frequency of blood glucose monitoring.</li></ul></li></ul><h5>Optimal blood glucose targets</h5><ul><li>For pre-prandial targets: <ul><li>One RCT identified by NICE reported that nocturnal hypoglycaemia was unlikely to occur if people with type 1 diabetes achieved a plasma glucose level above 5.5 mmol/L on waking.</li><li>A second RCT reported that the risk of overnight hypoglycaemia was reduced if a waking plasma glucose level above 5 mmol/L was achieved.</li><li>The NICE GDG recognized that these recommendations were in line with recommendations from intensive education courses for type 1 diabetes and that targets for morning blood glucose levels on waking should be higher than other fasting values through the day in order to reduce the risk of nocturnal hypoglycaemia. </li><li>The GDG, therefore, recommends that in adults with type 1 diabetes, fasting plasma glucose targets should be 5–7 mmol/L on waking in the morning and 4–7 mmol/L at other times of day.</li></ul></li><li> For post-prandial glucose targets: <ul><li>One large RCT reported that the risk of complications from retinopathy were greatly reduced if a plasma glucose level of less than 8.1 mmol/L could be achieved after meals. </li><li>Therefore, the NICE GDG considered that people with type 1 diabetes should aim for a blood glucose level that was not above 9 mmol/L postprandially, whilst also avoiding hypoglycaemia (best avoided by keeping plasma glucose targets always above 4.5 mmol/L).</li></ul></li><li>The NICE GDG recommends that a bedtime target plasma glucose levels should be agreed with the person with type 1 diabetes. This should take into account the timing of the last meal and its related insulin dose, and be consistent with the recommended fasting level on waking. If the person experiences overnight hypoglycaemia whilst trying to achieve these targets, this suggests that their basal and/or prandial insulin doses should be reviewed rather than adjustment of target blood glucose levels.</li></ul><h5>Timing of self-monitoring of blood glucose</h5><ul><li>Although evidence identified by NICE showed that increased frequency of testing was associated with improved blood glucose control, it did not suggest an advantage in testing at specified times of day.</li><li>The NICE GDG noted that current clinical practice is to test blood glucose levels on waking, before meals, and before bed, as there is concern that testing blood glucose after meals might lead to over correction of blood glucose levels if they were found to be high (although there is no clinical evidence from an RCT to support this concern). </li><li>Based on this, the GDG recommends testing blood glucose levels 4 times a day, including before meals and before bed. </li><li>The GDG concluded that further research is required to ascertain the importance of testing after meals compared with testing before meals, but acknowledged that testing after meals may be useful for educational purposes (for example when learning to carbohydrate count) and may help people to ensure they are taking adequate amounts of insulin at meal times.</li><li>The GDG emphasized that structured education in interpreting blood glucose values (for example in relation to food, illness, and recent exercise) is essential to allow people to make informed decisions about insulin dose adjustment for improved blood glucose control.</li></ul><h5>Continuous glucose monitoring </h5><ul><li>Evidence identified by NICE does not support the routine use of continuous glucose monitoring. However, the NICE GDG recognized that it may be a suitable option in situations in which routine management fails to control episodes of hypoglycaemia despite efforts to optimize both monitoring and treatment. The GDG did not want their recommendations to remove the possibility of using continuous glucose monitoring in such cases and therefore agreed on recommendations that set out the situations in which a trial of continuous glucose monitoring might be warranted.</li><li>The definition of continuous glucose monitoring is taken from review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Edelman, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ajjan, 2019</a>].</li></ul><!-- end field 7e2bc67e-5bc5-45f2-9f55-abe6013cb289 --><!-- end item 4dd37b4f-6d39-452a-8eb5-abe6013cb289 --></div></section></section><section aria-labelledby="lifestyle-management" class="ChapterBody-module--wrapper--2HCfk "><h3 id="lifestyle-management">Lifestyle management</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e19ce8e0-788f-471e-abbb-8f47d7cc7e33 --><!-- begin field fe6a882e-53cb-43e8-9dbb-668c43485c34 --><ul><li>See the sections on <a class="topic-reference internal-reference" href="index.html#diet">Diet</a>, <a class="topic-reference internal-reference" href="index.html#exercise-physical-activity">Exercise</a>, <a class="topic-reference internal-reference" href="index.html#alcohol-intake">Alcohol intake</a>, and <a class="topic-reference internal-reference" href="index.html#smoking-substance-misuse">Substance misuse</a> for information on managing these lifestyle issues. </li><li>Information on managing other lifestyle and cultural issues, such as driving, fasting, holiday and travel, and shift work, are available in the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#lifestyle-cultural-issues">Additional information and advice</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a>.</li></ul><!-- end field fe6a882e-53cb-43e8-9dbb-668c43485c34 --><!-- end item e19ce8e0-788f-471e-abbb-8f47d7cc7e33 --></div><section aria-labelledby="diet" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diet">Advice on diet</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5d030f64-bb56-41d1-8b2e-3d86754e275d --><!-- begin field afbf7bb5-3da8-438a-b35e-cfa51599f68a --><ul><li><strong>Provide information on the effects of different foods and drinks on blood glucose control.</strong><ul><li>Do not advise a low glycaemic index diet for blood glucose control.</li><li>Offer carbohydrate-counting training (a meal planning technique for managing blood glucose levels by matching carbohydrate quantities to insulin doses) as part of the <a class="topic-reference internal-reference" href="index.html#initial-care-support">structured education programme</a> for self-management. <ul><li>Consider carbohydrate-counting courses for people who are waiting for a more detailed structured education programme or are unable to take part in a stand-alone structured education programme. </li></ul></li><li>Refer the person to the specialist diabetes team (or make programmes available) to enable them to make optimal choices about the variety of foods they wish to consume and on appropriate insulin dose changes when taking different quantities of those foods. <ul><li>The Diabetes UK website (<a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/" data-hyperlink-id="1183e451-e32a-4c61-a200-a931009c5d97">www.diabetes.org.uk</a>) has dietary information for people with type 1 diabetes, including information on <a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/Carbohydrates-and-diabetes/" data-hyperlink-id="cf8e796b-1625-4e89-910e-a931009c5dc1">carbohydrates and diabetes</a>, what to <a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/Food-and-diabetes/I-have-Type-1-diabetes/What-can-I-eat-type-1/" data-hyperlink-id="c187f18c-7499-46a9-ba18-a931009c62b3">eat</a> and <a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/what-to-drink-with-diabetes/" data-hyperlink-id="9503bc28-7ba9-4133-9d8f-a931009c661b">drink</a>, <a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/Food-shopping-for-diabetes/" data-hyperlink-id="939a8684-abd6-4734-a445-a931009c6a51">food shopping tips</a>, and <a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/Carbohydrates-and-diabetes/how-to-cut-down-on-sugar/" data-hyperlink-id="fe32e8c1-0985-44a7-8277-a931009c6eb6">how to cut down on sugar</a>. </li></ul></li></ul></li><li><strong>Provide dietary information for the prevention of cardiovascular disease (CVD). </strong><ul><li>Advise adults with type 1 diabetes on the importance of a healthy, balanced diet in reducing the risk of CVD. The diet should be low in fat, sugar, and salt, and contain at least 5 portions of fruit and vegetables a day.</li><li>If necessary, offer dietetic support (or advise the person to contact their specialist diabetes team) to help optimize body weight and blood glucose control.</li></ul></li><li><strong>Modify nutritional recommendations to take account of associated features of diabet</strong><strong>es, including:</strong><ul><li>Excess weight and obesity. See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for management information.</li><li>Being underweight.</li><li>Eating disorders. See the CKS topic on <a class="topic-reference external-reference" href="../../../eating-disorders/index.html">Eating disorders</a> for management information.</li><li>Hypertension. See the section on <a class="topic-reference internal-reference" href="index.html#antihypertensive-treatment">Antihypertensive treatment</a> for management information.</li><li>Chronic kidney disease (CKD). See the section on <a class="topic-reference internal-reference" href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a> for management information.</li></ul></li><li><strong>Be aware of appropriate nutritional advice on common topics of concern and interest to adults with type 1 diabetes.</strong><ul><li>These may include:<ul><li>Body weight, energy balance, and obesity management.</li><li>Cultural and religious diets, feasts, and fasts. </li><li>Diabetic foods and sweeteners.</li><li>Dietary fibre and protein intake.</li><li>Vitamin and mineral supplements.</li><li>Alcohol intake.</li><li>Matching carbohydrate, insulin, and physical activity.</li><li>Salt intake in hypertension.</li><li>Comorbidities, including nephropathy and renal failure, coeliac disease, cystic fibrosis, or eating disorders.</li><li>Use of peer support groups. </li></ul></li><li>Refer the person to a dietitian or the specialist diabetes team for information on these and other dietary issues.</li></ul></li></ul><!-- end field afbf7bb5-3da8-438a-b35e-cfa51599f68a --><!-- end item 5d030f64-bb56-41d1-8b2e-3d86754e275d --></div></section><section aria-labelledby="alcohol-intake" class="ChapterBody-module--wrapper--2HCfk "><h4 id="alcohol-intake">Advice on alcohol intake</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3388f801-6466-40df-bfdf-5829636a8443 --><!-- begin field e4b28f28-19a3-4e79-a42a-569407706c75 --><ul><li><strong>Advise the person with type 1 diabetes and/or their family/carers:</strong><ul><li>To avoid drinking alcohol on an empty stomach as the alcohol will be absorbed faster. They should:<ul><li>Eat a snack that contains carbohydrate (such as a sandwich or crisps) before and after drinking alcohol. Extra insulin is not required.</li><li>Measure their blood glucose regularly, and maintain their blood glucose with appropriate carbohydrate intake.</li></ul></li><li>That alcohol may exacerbate or prolong the hypoglycaemic effect of insulin, including nocturnal hypoglycaemia.<ul><li>Signs of hypoglycaemia may become less clear, and delayed hypoglycaemia may occur (which can be hours after alcohol consumption).</li><li>See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#managing-hypoglycaemia">hypoglycaemia</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for detailed information on hypoglycaemia.</li></ul></li><li>To always wear some form of diabetes identification as the reduced awareness of hypoglycemia may be confused with alcohol intoxication. Examples of diabetes identification include:<ul><li>A MedicAlert® bracelet, necklace, or watch (available from <a style="background-color: #ffffff;" href="http://www.medicalert.org.uk/" data-hyperlink-id="4557d66a-78c4-4822-ad7b-a9310098380e">www.medicalert.org.uk</a>).</li><li>Diabetes ID Card (available from <a href="https://www.diabetes.co.uk/diabetic-products/medipal-card.html" data-hyperlink-id="14cb21a9-e88b-4bda-8269-abf6016c0b10">www.diabetes.co.uk</a>).</li></ul></li></ul></li><li><strong>Give information on the recommended maximum alcohol intake.</strong><ul><li>The <a href="http://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/545739/GDG_report-Jan2016.pdf" data-hyperlink-id="633e12bc-4c45-49d1-912a-abf60119588e">Chief Medical Officers' guideline</a> for both men and women states that:<ul><li>It is safest not to regularly drink more than 14 units of alcohol per week, to keep health risks from drinking alcohol to a low level.</li><li>People who drink as much as 14 units of alcohol per week should spread this evenly over 3 days or more. One or two heavy drinking sessions increases the risk of death from long-term illnesses and from accidents and injuries.</li><li>The risk of developing a range of illnesses (such as cancers of the mouth, throat, and breast) increases with any amount of alcohol consumed on a regular basis.</li><li>If people wish to cut down the amount of alcohol they are drinking, a good way to help achieve this is to have several drink-free days each week.</li><li>For women who are pregnant or planning a pregnancy, the safest approach is not to drink alcohol at all, to keep risks to the baby to a minimum.</li></ul></li><li>See the section on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/background-information/definition/index.html#unit-of-alcohol">Unit of alcohol</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/index.html">Alcohol - problem drinking</a> for more information on alcohol units.</li><li>Information on <a href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/what-to-drink-with-diabetes/Alcohol-and-diabetes" data-hyperlink-id="c9397b2f-dde1-4e5f-9628-abc60085776e">Alcohol and diabetes</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/young-adults/type-1-drinking" data-hyperlink-id="33645533-969d-4624-b53b-abc6008dfa2d">Type 1 diabetes and drinking</a> are also available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/" data-hyperlink-id="34be83a3-1ff2-4ea8-adf7-abc600857a1f">www.diabetes.org.uk</a>).</li></ul></li></ul><!-- end field e4b28f28-19a3-4e79-a42a-569407706c75 --><!-- end item 3388f801-6466-40df-bfdf-5829636a8443 --></div></section><section aria-labelledby="exercise-physical-activity" class="ChapterBody-module--wrapper--2HCfk "><h4 id="exercise-physical-activity">Advice on exercise and physical activity</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9502ed81-54a7-4e6a-9938-ef7d370ef0d2 --><!-- begin field d6b387cb-d47f-449f-bc85-348e90a729fc --><ul><li><strong>Advise adults with type 1 diabetes that regular exercise:</strong><ul><li>May lower blood glucose levels, as exercise increases the amount of glucose used by the muscles for energy.</li><li>Can reduce the increased cardiovascular risk in the medium and longer term. </li><li>Can help with weight management (when combined with a healthy diet). See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li><strong>Ensure the person has information on:</strong><ul><li>The role of <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">self-monitoring</a> on changed insulin and/or nutritional needs. </li><li>The effect of activity on blood glucose levels when insulin levels are adequate (risk of hypoglycaemia).</li><li>The effect of exercise on blood glucose levels when the person is hyperglycaemic or hypoinsulinaemic (risk of worsening of hyperglycaemia and ketonaemia).</li><li>The appropriate adjustments of insulin dosage and/or nutritional intake for exercise and post-exercise periods, and the next 24 hours.</li><li>Interactions of exercise and alcohol.</li><li>Further contacts and sources of information. Information on <a href="https://www.diabetes.org.uk/Guide-to-diabetes/Managing-your-diabetes/Exercise" data-hyperlink-id="91f34bf4-222a-40ef-97a1-abc6008934bf">Diabetes and exercise</a> is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/" data-hyperlink-id="14e7976e-2a44-493a-9257-abc6008936e5">www.diabetes.org.uk</a>).  </li></ul></li><li><strong>For people who choose to integrate increased physical activity into a more healthy lifestyle, provide information on the appropriate intensity and frequency. </strong>The current <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/832868/uk-chief-medical-officers-physical-activity-guidelines.pdf" data-hyperlink-id="2563ca7e-8685-4f1d-9b4b-abc600897a4c">UK Chief Medical Officers' Physical Activity Guidelines</a> state that:<ul><li><strong>Adults aged 19–64 years should:</strong><ul><li>Aim to be physically active every day for good physical and mental health.</li><li>Do activities to develop or maintain strength in the major muscle groups. These could include heavy gardening, carrying heavy shopping, or resistance exercise. Muscle strengthening activities should be done on at least two days a week, but any strengthening activity is better than none.</li><li>Each week, accumulate at least 150 minutes of moderate intensity activity (such as brisk walking or cycling), or 75 minutes of vigorous intensity activity (such as running), or shorter durations of very vigorous intensity activity (such as sprinting or stair climbing), or a combination of moderate, vigorous, and very vigorous intensity activity.</li><li>Aim to minimize the amount of time spent being sedentary and when physically possible should break up long periods of inactivity with at least light physical activity.</li></ul></li><li><strong>Older adults aged 65 years and over should:</strong><ul><li>Participate in daily physical activity to gain health benefits, including maintenance of good physical and mental health, wellbeing, and social functioning. Some physical activity is better than none; even light activity brings some health benefits compared with being sedentary, while more daily physical activity provides greater health and social benefits.</li><li>Maintain or improve their physical function by undertaking activities aimed at improving or maintaining muscle strength, balance, and flexibility on at least two days a week. These could be combined with sessions involving moderate aerobic activity or could be additional sessions aimed specifically at these components of fitness.</li><li>Each week, aim to accumulate 150 minutes of moderate intensity aerobic activity, building up gradually from current levels. Those who are already regularly active can achieve these benefits through 75 minutes of vigorous intensity activity or a combination of moderate and vigorous activity to achieve greater benefits. Weight-bearing activities that create an impact through the body help to maintain bone health.</li><li>Break up prolonged periods of being sedentary with light activity when physically possible, or at least with standing, as this has distinct health benefits for older people.</li></ul></li></ul></li></ul><!-- end field d6b387cb-d47f-449f-bc85-348e90a729fc --><!-- end item 9502ed81-54a7-4e6a-9938-ef7d370ef0d2 --></div></section><section aria-labelledby="smoking-substance-misuse" class="ChapterBody-module--wrapper--2HCfk "><h4 id="smoking-substance-misuse">Advice on smoking and substance misuse</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a7404c90-d156-49e0-b2ea-c3ed84231218 --><!-- begin field 5f068419-ba85-4b7a-8b22-5a67983fec07 --><ul><li><strong>Explain that smoking is a risk factor for cardiovascular disease. </strong><ul><li>Give adults with type 1 diabetes who smoke advice on smoking cessation and the use of smoking cessation services. <ul><li>Reinforce this advice annually for people who currently do not plan to stop smoking, and at all clinical contacts if there is a prospect of the person stopping. </li></ul></li><li>Advise young adult non-smokers never to start smoking.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for information on smoking cessation and smoking cessation services.</li></ul></li><li><strong>Explain about the general dangers of substance misuse and the possible effects on blood glucose control.</strong><ul><li>Information, advice, and support on substance misuse are available on the Talk to Frank website (<a style="background-color: #ffffff;" href="http://www.talktofrank.com/" data-hyperlink-id="e3f1bf10-9796-4e76-806b-a93100a4c7a6">www.talktofrank.com</a>).</li></ul></li></ul><!-- end field 5f068419-ba85-4b7a-8b22-5a67983fec07 --><!-- end item a7404c90-d156-49e0-b2ea-c3ed84231218 --></div></section><section aria-labelledby="basis-for-recommendation-14b" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-14b">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 14b41f64-929a-4dfa-820d-f5e593e12642 --><!-- begin field 690d2ff0-0e4a-4e26-80dc-1dfb105daa1b --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng17/evidence/full-guideline-pdf-435400241" data-hyperlink-id="0da19505-b35e-4c8a-9c90-a93100987082">full NICE guideline</a>.</p><h5>Advice on diet</h5><ul><li><strong>Information and advice</strong><ul><li>NICE recommends providing appropriate nutritional advice to people with type 1 diabetes and/or their family/carers to enable them to make appropriate dietary choices and insulin dose adjustments. </li></ul></li><li><strong>Low glycaemic index (GI) diet</strong><ul><li>Very low- to low-quality evidence identified by NICE (from one randomized and four non-randomized controlled trials) did not show any benefit of a low GI diet on blood glucose control (assessed by reduction in HbA1c), frequency of hypoglycaemia (including severe hypoglycaemia), and adverse effects.</li><li>The NICE guideline development group (GDG) recognized that there are theoretical reasons why a low GI diet might lead to improved blood glucose control and that post-prandial glucose levels might be reduced with a low GI diet. However, as there are currently no long-term trials assessing the impact of a low fat, low GI diet on the incidence of microvascular complications, the GDG concluded that further research is needed before this diet can be offered to people with type 1 diabetes.</li></ul></li><li><strong>Carbohydrate counting</strong><ul><li>Carbohydrates are the macronutrient with the greatest impact on blood glucose control, and it is well known that total carbohydrate (or glycaemic load) is the main predictor of the rise in blood glucose levels after meals.</li><li>Moderate, low, and very low-quality evidence identified by NICE (mainly from single studies) showed a clinical benefit of carbohydrate counting for HbA1c (change from baseline) at up to 6 months and over 6 months, and mild hypoglycaemia at over 6 months. However, low- and very low-quality evidence from single studies showed no clinical benefit of carbohydrate counting for HbA1c (final values) at over 6 months.</li><li>Low-quality evidence from a single observational study (case-series, before and after study) showed that compared with baseline, there were improvements in HbA1c after people used carbohydrate counting. </li></ul></li></ul><h5>Advice on exercise and physical activity</h5><ul><li>NICE reviewed the available evidence assessing the impact of exercise and physical activity on adults with type 1 diabetes. Although there was evidence for an improved arterial risk profile, evidence of a consistent effect in improving blood glucose control was absent. </li><li>However, given the fact that exercise and increased physical activity are usually recommended to the general population as part of a package of lifestyle measures to improve future health, in particular reduction of arterial risk (which is markedly elevated in people with type 1 diabetes), NICE recommends that appropriate information should be given to adults with type 1 diabetes who wish to integrate physical activity into a more healthy lifestyle.</li></ul><h5>Advice on alcohol intake</h5><ul><li>NICE recommends that adults with type 1 diabetes should be given appropriate information on the effects of alcohol on blood glucose control and exercise.</li><li>NICE does not make specific recommendations on what should be advised, so CKS has extrapolated recommendations from the NICE guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>] and from information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/what-to-drink-with-diabetes/alcohol-and-diabetes" data-hyperlink-id="34be83a3-1ff2-4ea8-adf7-abc600857a1f">www.diabetes.org.uk</a>).</li><li>The information on recommended alcohol units is taken from the <em>Alcohol Guidelines Review</em> published by the Department of Health [<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2016</a>].</li></ul><h5>Advice on smoking </h5><ul><li>This recommendation is based on the expert opinion of the NICE GDG.</li><li>The GDG noted that evidence identified in the Scottish Intercollegiate Guidelines Network (SIGN) guideline<em> Management of diabetes. A national clinical guideline</em> suggests that smoking is an independent risk factor for cardiovascular disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2017</a>].</li></ul><h5>Advice on substance misuse</h5><ul><li>CKS has extrapolated this recommendation from the NICE guideline<em> Diabetes (type 1 and type 2) in children and young people: diagnosis and management  </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>] as substance misuse can also be a problem in the adult population.</li></ul><!-- end field 690d2ff0-0e4a-4e26-80dc-1dfb105daa1b --><!-- end item 14b41f64-929a-4dfa-820d-f5e593e12642 --></div></section></section><section aria-labelledby="managing-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-hypoglycaemia">How should I manage an adult with hypoglycaemia?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 44dd8d64-4727-430d-9c8d-abb80153dc4e --><!-- begin field ffc8ec47-ac3f-4408-8856-abb80153dcc1 --><ul><li>See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#managing-hypoglycaemia">Hypoglycaemia</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for management information.</li></ul><!-- end field ffc8ec47-ac3f-4408-8856-abb80153dcc1 --><!-- end item 44dd8d64-4727-430d-9c8d-abb80153dc4e --></div></section><section aria-labelledby="managing-diabetic-ketoacidosis" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-diabetic-ketoacidosis">How should I manage an adult with diabetic ketoacidosis?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c734002a-f9d4-4824-b3e8-e60833abfbe6 --><!-- begin field f0bcd11d-57b9-453f-ae1c-6e813527695e --><ul><li><strong>If diabetic ketoacidosis (DKA) is <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-diabetic-ketoacidosis/index.html">suspected</a>, </strong>admit the person immediately for confirmation of the diagnosis and emergency treatment with intravenous insulin and fluids.</li><li><strong>After the person has recovered from an episode of DKA: </strong><ul><li>Discuss the <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-diabetic-ketoacidosis/index.html">factors</a> that may have led to the episode.<ul><li>If DKA is recurrent, consider the possibility of non-adherence to treatment or intentional insulin omission in order to lose weight (<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">diabulimia</a>).</li></ul></li><li>Give general information on DKA, including information on how to reduce the risk of future episodes.<ul><li>Information on DKA for people with type 1 diabetes and their family/carer is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/diabetic_ketoacidosis" data-hyperlink-id="a5ee0da5-1c79-4f79-b0d2-a9310098c826">www.diabetes.org.uk</a>).</li></ul></li><li>Ensure that the person is given appropriate information on how to manage diabetes during a period of illness (<a class="topic-reference internal-reference" href="index.html#sick-day-rules">'sick-day rules'</a>). </li></ul></li></ul><!-- end field f0bcd11d-57b9-453f-ae1c-6e813527695e --><!-- end item c734002a-f9d4-4824-b3e8-e60833abfbe6 --></div><section aria-labelledby="basis-for-recommendation-1e3" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-1e3">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1e3acb6b-2485-4e5c-b4a9-5f49134a3718 --><!-- begin field 6d45fe00-7f95-4920-be30-fbb7c3509dfc --><ul><li>Diabetic ketoacidosis (DKA) is a medical emergency. It has a high mortality rate if it is not managed promptly with close monitoring and careful correction of fluid and electrolyte imbalances [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint British Diabetes Societies Inpatient Care Group, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Karslioglu French, 2019</a>].</li><li>The recommendation to admit adults with suspected DKA and the advice on how to manage the person after an episode of DKA have been extrapolated from the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].</li><li>A <a href="http://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/2017-08/Diabulimia%20Position%20statement%20Mar%202017.doc" data-hyperlink-id="597277af-e86d-4b8e-b215-abe90097b83b">position statement</a> issued by Diabetes UK lists recurrent DKA and recurrent hospital admission for hyperglycaemia as possible signs of <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">diabulimia</a> (a 'disordered eating behaviour' in the practice of reducing or omitting insulin in order to lose weight).</li></ul><!-- end field 6d45fe00-7f95-4920-be30-fbb7c3509dfc --><!-- end item 1e3acb6b-2485-4e5c-b4a9-5f49134a3718 --></div></section></section><section aria-labelledby="managing-intercurrent-illness" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-intercurrent-illness">How should I manage an adult with type 1 diabetes during a period of illness?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 07fbca24-ea75-4483-a310-e4ced3fcfdfc --><!-- begin field 558213f0-2ae9-4299-8d60-208dad9cb6fd --><ul><li><strong>Consider the need for admission or specialist advice<em>.</em></strong> The decision will depend on clinical judgement, taking into account the person's age, any underlying illness or complications, and the presence of hyperglycaemia (random plasma glucose more than 11 mmol/L) and ketosis.<ul><li><strong>Arrange hospital admission if:</strong><ul><li>There is an immediate risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-diabetic-ketoacidosis/index.html">diabetic ketoacidosis</a> (DKA).</li><li>There is moderate ketonuria (2+ on urine dipstick) or ketonaemia (1.5–2.9 mmol/L) with or without hyperglycaemia and the person cannot eat or drink, as there is a risk of DKA.</li><li>The person does not improve rapidly with insulin treatment.</li></ul></li><li><strong>Consider arranging hospital admission or seeking urgent specialist advice if:</strong><ul><li>The underlying condition is unclear.</li><li>The person is dehydrated or at risk of dehydration.</li><li>Vomiting persists beyond 2 hours.</li><li>The person and their family/carers are unable to keep the blood glucose level above 3.5 mmol/L.</li><li>The person is on continuous subcutaneous insulin pump therapy. See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#recommended-insulin-regimen">Insulin pump therapy</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a>.</li><li>The person and their family/carers are exhausted, for example due to repeated night-time waking.</li><li>Language problems make it difficult to communicate with the person and/or their family/carers.</li></ul></li></ul></li><li><strong>If the person can be managed in primary care:</strong><ul><li>Assess and manage the intercurrent illness.</li><li>Assess how well blood glucose has been monitored and managed with diet and insulin.</li><li>Warn the person and their family/carers that illness may affect blood glucose control:<ul><li>Some illnesses (especially if associated with fever) can raise blood glucose levels.</li><li>In contrast, illnesses associated with vomiting and diarrhoea (such as gastroenteritis) can lower blood glucose levels, possibly leading to hypoglycaemia (blood glucose levels less than 3.5 mmol/L).</li></ul></li><li>Ensure that the person has:<ul><li>Written <a class="topic-reference internal-reference" href="index.html#sick-day-rules">'sick-day rules'</a> and contact details of the healthcare team.</li><li>Easily digestible food and sugary drinks (to provide energy and to prevent further ketosis).</li><li>Oral rehydration salt sachets (to prevent dehydration).</li><li>Additional supplies of insulin.</li><li>Glucose tablets or oral gel (to prevent hypoglycaemia).</li><li>A glucagon kit (if appropriate).</li></ul></li></ul></li></ul><!-- end field 558213f0-2ae9-4299-8d60-208dad9cb6fd --><!-- end item 07fbca24-ea75-4483-a310-e4ced3fcfdfc --></div><section aria-labelledby="sick-day-rules" class="ChapterBody-module--wrapper--2HCfk "><h4 id="sick-day-rules">What are the 'sick-day rules' for adults with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7e705ec1-c06a-41b5-9a88-3eb68087af41 --><!-- begin field 33b19b56-bc05-4e59-9785-71252703e238 --><ul><li><strong>During a period of illness that does </strong><strong>not require admission</strong><strong>, r</strong><strong>emind the person to adhere to the 'sick-day rules' that should have been provided by their diabetes team. </strong>They should:<ul><li><strong>Never stop or omit insulin.</strong><ul><li>The dose of insulin may need to be altered during periods of illness; they should seek advice from their diabetes team if they are unsure of how to adjust insulin doses.</li></ul></li><li><strong>Check blood glucose more frequently, for example every 1–2 hours including through the night.</strong><ul><li>The insulin dose should be titrated according to the blood glucose results and the written 'sick-day rules'.</li></ul></li><li><strong>Consider checking blood or urine ketone levels regularly,</strong> for example every 3–4 hours including through the night, and sometimes every 1–2 hours depending on results.<ul><li>If the urine ketone level is greater than 2+ or blood ketone levels are greater than 3 mmol/L, the person should contact the GP or diabetes care team immediately.</li></ul></li><li><strong>Maintain their normal meal pattern (where possible) if appetite is reduced. </strong><ul><li>Their normal meals could be replaced with carbohydrate-containing drinks (such as milk, milk shakes, fruit juices, and sugary drinks).</li></ul></li><li><strong>Aim to drink at least 3 L of fluid (5 pints) a day to prevent dehydration.</strong><ul><li>If blood glucose levels are normal or high, water or sugar-free fluids are probably most appropriate in the majority of cases.</li><li>If blood glucose levels are low, drinks containing glucose are required (or the person should take carbohydrates if possible).</li><li>Carbonated drinks should be avoided if possible.</li></ul></li><li><strong>Seek urgent medical advice if they are violently sick, drowsy, or unable to keep fluids down.</strong><ul><li>Intravenous fluids may be required.</li></ul></li><li><strong>When feeling better, continue to monitor their blood glucose carefully until it returns to normal.</strong><ul><li>This may take some time.</li><li>The person should seek medical advice if their blood glucose remains uncontrolled.</li></ul></li></ul></li><li><strong>Further patient information on managing diabetes during a period of illness is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Illness/" data-hyperlink-id="ae69346e-4409-4f31-9cfe-a9310097fcc0">www.diabetes.org.uk</a>).</strong></li></ul><!-- end field 33b19b56-bc05-4e59-9785-71252703e238 --><!-- end item 7e705ec1-c06a-41b5-9a88-3eb68087af41 --></div></section><section aria-labelledby="basis-for-recommendation-a04" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-a04">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a04d77d0-7f54-42e4-be4e-8f147d898a33 --><!-- begin field c88186e3-b597-4372-a495-8bf6a2392380 --><h5>Managing a period of illness</h5><ul><li>These recommendations are extrapolated from the Association of Children's Diabetes Clinicians and British Society for Paediatric Endocrinology and Diabetes (BSPED) <em>Clinical guideline. Management of type 1 diabetes mellitus during illness in children and young people under 18 years (sick day rules)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ng, 2018</a>], the <em>ISPAD Clinical Practice Consensus Guidelines 2018: Sick day management in children and adolescents with diabetes </em>published by the International Society for Pediatric and Adolescent Diabetes (ISPAD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Laffel, 2018</a>], and the <em>National Service Framework for Children, Young People and Maternity Services – Diabetes Type 1 in childhood and adolescence</em> published by the Department of Health and Diabetes UK [<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2010</a>].</li></ul><h5>'Sick-day rules'</h5><ul><li>The National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>] recommends that clear guidelines and protocols ('sick-day rules') are given to all adults with type 1 diabetes to help them adjust insulin doses appropriately during periods of illness. However, NICE does not specify these guidelines and protocols. The recommended 'sick-day rules' are based on information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Life-with-diabetes/Illness" data-hyperlink-id="00793989-e848-4087-8956-a93100b5838f">www.diabetes.org.uk</a>). Some recommendations, including the frequency of blood glucose monitoring, have been extrapolated from the Association of Children's Diabetes Clinicians and BSPED guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ng, 2018</a>] and the ISPAD consensus guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Laffel, 2018</a>]<em>.</em></li><li>The NICE guideline recommends that ketone monitoring (blood or urine) should be considered as part of 'sick-day rules' for adults with type 1 diabetes, to facilitate self-management of an episode of hyperglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. However, it does not specify how often the monitoring should be done. The recommended monitoring frequency is based on what CKS considers to be good clinical practice.</li></ul><h5>Effect of illness on diabetes</h5><ul><li>According to the Association of Children's Diabetes Clinicians and BSPED guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ng, 2018</a>]:<ul><li>Illness generally raises blood glucose levels and increases the risk of ketone body production due to a relative deficiency of insulin.</li><li>Increased levels of stress hormones during illness contribute to high blood glucose levels.</li><li>Cytokine release in response to infection can also lead to some degree of insulin resistance.</li><li>Diarrhoea and vomiting may reduce blood glucose levels with a possibility of hypoglycaemia rather than hyperglycaemia.</li><li>Ketones may still be produced in significant quantities even with hypoglycaemia in people with gastroenteritis.</li></ul></li></ul><!-- end field c88186e3-b597-4372-a495-8bf6a2392380 --><!-- end item a04d77d0-7f54-42e4-be4e-8f147d898a33 --></div></section></section><section aria-labelledby="managing-cardiovascular-risk" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-cardiovascular-risk">How should I manage cardiovascular risk factors in adults with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 532ef973-0dd8-4b7f-a42e-18d3ff101ca8 --><!-- begin field 8264cb60-f42c-4943-a829-e872be9de53e --><ul><li><strong>Assess the following cardiovascular risk factors annually:</strong><ul><li><strong>Lifestyle, including smoking status.</strong><ul><li>See the sections on <a class="topic-reference internal-reference" href="index.html#diet">Diet</a>, <a class="topic-reference internal-reference" href="index.html#exercise-physical-activity">Exercise</a>, <a class="topic-reference internal-reference" href="index.html#alcohol-intake">Alcohol intake</a>, and <a class="topic-reference internal-reference" href="index.html#smoking-substance-misuse">Substance misuse</a> for information on managing these lifestyle issues. </li></ul></li><li><strong>Waist circumference.</strong><ul><li>The waist circumference provides an indication of total body fat and a risk of obesity-related health problems.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li><strong>Blood glucose control.</strong><ul><li>Advise on the importance of adequate blood glucose control. </li><li>Reiterate <a class="topic-reference internal-reference" href="index.html#target-hba1c">HbA1c</a> and <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">glucose self-monitoring</a> targets.</li></ul></li><li><strong>Blood pressure.</strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#antihypertensive-treatment">Antihypertensive treatment</a> for more information.</li></ul></li><li><strong>Albuminuria. </strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a> for more information.</li></ul></li><li><strong>Full lipid profile </strong>(high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and triglycerides).<ul><li>Offer a statin for the prevention of cardiovascular disease (CVD).</li><li>See the section on <a class="topic-reference internal-reference" href="index.html#lipid-modification">Lipid modification therapy</a> for more information.</li></ul></li><li><strong>Family history of CVD.</strong></li></ul></li><li><strong>Provide intensive management for adults who have had myocardial infarction or stroke.</strong><ul><li>Consider a beta blocker in people with angina or other ischaemic heart disease. See the CKS topics on <a class="topic-reference external-reference" href="../../../mi-secondary-prevention/index.html">MI - secondary prevention</a> and <a class="topic-reference external-reference" href="../../../stroke-tia/index.html">Stroke and TIA</a> for more information. </li><li><strong>Do not offer aspirin for the primary prevention of CVD.</strong> <ul><li>Decisions about antiplatelet treatment will usually be made by, or in consultation with, secondary care.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../antiplatelet-treatment/index.html">Antiplatelet treatment</a> for information on the use of aspirin for the secondary prevention of CVD.</li></ul></li></ul></li></ul><!-- end field 8264cb60-f42c-4943-a829-e872be9de53e --><!-- end item 532ef973-0dd8-4b7f-a42e-18d3ff101ca8 --></div><section aria-labelledby="antihypertensive-treatment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="antihypertensive-treatment">Antihypertensive treatment</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e4e8d7df-b593-441c-b19f-bdfbea1b04c9 --><!-- begin field 2242be2c-3643-4e14-b899-f2084053cdea --><ul><li><strong>If there is no <a class="topic-reference internal-reference" href="index.html#diabetic-kidney-disease">albuminuria</a> or <a class="topic-reference internal-reference" href="index.html#basis-for-recommendation-1a7">features of the metabolic syndrome</a>, </strong>the threshold for starting antihypertensive treatment in an adult with type 1 diabetes is blood pressure greater than or equal to 135/85 mmHg.</li><li><strong>If there is albuminuria or two or more features of the metabolic syndrome,</strong> the threshold for starting antihypertensive treatment is blood pressure greater than or equal to 130/80 mmHg.</li><li><strong>Start a trial of a renin-angiotensin system blocking drug as first-line treatment for hypertension in adults with type 1 diabetes.</strong><ul><li>Offer an angiotensin-converting enzyme (ACE) inhibitor, provided there are no contraindications. If an ACE inhibitor is not tolerated, offer an angiotensin-II receptor antagonist (AIIRA) if appropriate.<ul><li>Start with a low dose and titrate up to the maximum tolerated therapeutic dose (within the maximum licensed dose) by doubling the dose every 1–2 weeks.</li><li>After each upward titration, monitor the person's renal function, serum potassium level, and blood pressure.</li><li>See the section on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/prescribing-information/index.html">Prescribing information</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for detailed information on prescribing ACE inhibitors and AIIRAs.</li></ul></li><li>Provide information on the potential for lifestyle changes to improve blood pressure control and associated outcomes. See the sections on <a class="topic-reference internal-reference" href="index.html#smoking-substance-misuse">Smoking</a>, <a class="topic-reference internal-reference" href="index.html#diet">Diet</a>, and <a class="topic-reference internal-reference" href="index.html#exercise-physical-activity">Exercise</a> for more information.</li><li>Be aware that it may be necessary to prescribe other antihypertensive drugs to improve blood pressure control.<ul><li>Do not avoid cardioselective beta-blockers (such as atenolol and metoprolol) where indicated in adults on insulin.</li><li>Low-dose thiazides may be combined with beta-blockers.</li><li>When calcium-channel blockers are prescribed, use only long-acting preparations.</li><li>For information on managing hypertension in adults with type 1 diabetes and nephropathy, see the section on <a class="topic-reference internal-reference" href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a>.</li></ul></li></ul></li></ul><!-- end field 2242be2c-3643-4e14-b899-f2084053cdea --><!-- end item e4e8d7df-b593-441c-b19f-bdfbea1b04c9 --></div></section><section aria-labelledby="lipid-modification" class="ChapterBody-module--wrapper--2HCfk "><h4 id="lipid-modification">Lipid modification therapy</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 306083c4-7567-479a-8c9c-bd5c02b0e9ec --><!-- begin field d0a29200-880e-45f0-8ebd-a495834e107e --><p><strong>Do not use a risk assessment tool to assess cardiovascular disease (CVD) risk in people with type 1 diabetes.</strong></p><ul><li><strong>For people with type 1 diabetes who do not have established CVD </strong>(for example a history of myocardial infarction, angina, stroke, transient ischaemic attack, or peripheral arterial disease):<ul><li>Offer statin treatment with atorvastatin 20 mg for the primary prevention of CVD if the person:<ul><li>Is older than 40 years of age, <em>or</em></li><li>Has had diabetes for more than 10 years, <em>or</em></li><li>Has established nephropathy, <em>or</em></li><li>Has other CVD risk factors (such as obesity and hypertension).</li></ul></li><li>For all other adults with type 1 diabetes, consider statin treatment with atorvastatin 20 mg for the primary prevention of CVD.</li></ul></li><li><strong>For people with type 1 diabetes who have established CVD:</strong><ul><li>Advise statin treatment with atorvastatin 80 mg for the secondary prevention of CVD.</li></ul></li><li><strong>Before initiating treatment with a statin:</strong><ul><li>Implement measures to reduce the risk of CVD. These are discussed in detail in the CKS topic on <a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a>, and include:<ul><li>Addressing other modifiable CVD risk factors, such as smoking.</li><li>Identifying and managing secondary causes of hyperlipidaemia, such as excess alcohol consumption, hypothyroidism, liver disease, and nephrotic syndrome.</li></ul></li><li>Have an informed discussion with the person and/or their family/carers about the risks and benefits of statin treatment, taking into account additional factors, such as potential benefits from lifestyle modifications, the person's preference, comorbidities, polypharmacy, general frailty, and life expectancy. Advise that:<ul><li>Statin treatment reduces CVD risk compared with no treatment.</li><li>The adverse effects of statins are generally mild, reversible, and not medically serious, although some people may find them distressing.</li><li>Myopathy and rhabdomyolysis are the most serious adverse effects of statins. However, they are rare, with estimated incidences of 5 cases per 100,000 person-years and 1.6 cases per 100,000 person-years, respectively.</li></ul></li><li>Perform baseline blood tests to ensure that statin treatment is suitable. This should include:<ul><li>A non-fasting lipid profile, liver function tests, and renal function.</li><li>Thyroid stimulating hormone — if hyperlipidaemia is present.</li><li>Creatine kinase — if the person has persistent generalized unexplained muscle pain.</li></ul></li></ul></li><li><strong>See the CKS topic on <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for detailed information on the baseline tests, how to initiate statin treatment, and how to monitor a person taking a statin.</strong></li></ul><!-- end field d0a29200-880e-45f0-8ebd-a495834e107e --><!-- end item 306083c4-7567-479a-8c9c-bd5c02b0e9ec --></div></section><section aria-labelledby="basis-for-recommendation-1a7" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-1a7">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1a7263e6-d573-4e0d-8e06-132202f7be79 --><!-- begin field fd381c75-45cd-4d2c-a974-f8a48794c19a --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng17/evidence/full-guideline-pdf-435400241" data-hyperlink-id="0da19505-b35e-4c8a-9c90-a93100987082">full NICE guideline</a>.</p><h5>Assessment</h5><ul><li>NICE advises that people with type 1 diabetes should have their cardiovascular risk factors assessed annually. <ul><li>The combination of hypertension and nephropathy, or features of the metabolic syndrome is known to be very high risk for premature cardiovascular disease (CVD) in early middle age<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].</li><li>The metabolic syndrome is generally defined as the presence of any three (or more) of the following factors [<a class="bibliography-reference internal-reference" href="../../references/index.html">IDF, 2006</a>]:<ul><li>Increased waist circumference. This is ethnicity specific, for example 94 cm or more in Caucasian men and 90 cm or more in South Asian men. If body mass index (BMI) is over 30 kg/m<sup>2</sup>, central obesity can be assumed, and waist circumference does not need to be measured.</li><li>Raised triglycerides (or on specific treatment for this lipid abnormality).</li><li>Reduced high-density lipoprotein (HDL) cholesterol (or on specific treatment for this lipid abnormality).</li><li>Raised blood pressure (or on treatment for previously diagnosed hypertension).</li><li>Raised blood glucose.</li></ul></li></ul></li></ul><h5>Antihypertensive treatment</h5><ul><li><strong>Treatment target</strong><ul><li>NICE identified two large multicentre trials included in a systematic review that showed an improvement in arterial and microvascular outcomes in people randomized to lower target blood pressures compared with those with less intensive blood pressure lowering.</li><li>NICE found evidence to support a diastolic blood pressure of less than 80 mmHg. No evidence on the appropriate target systolic blood pressure for people with type 1 diabetes was identified; however, the NICE GDG noted that consensus recommendations from the Canadian Hypertension Recommendations working group are that systolic blood pressure should be less than 130 mmHg [<a class="bibliography-reference internal-reference" href="../../references/index.html">McAlister, 2002</a>].</li><li>The NICE guideline development group (GDG) pointed out that because the combination of raised blood pressure and nephropathy, or the presence of two or more features of the metabolic syndrome is known to be very high risk for premature CVD, intervention levels and targets should be lower and more strictly applied in this case than for a person with simple hypertension. </li></ul></li><li><strong>Antihypertensive drug choices</strong><ul><li>The NICE GDG did not review the evidence for the recommended antihypertensive drug treatments for people with type 1 diabetes, but were aware that several studies provide evidence for the safety and efficacy of renin-angiotensin system (RAS) blockers, calcium-channel blockers, and low-dose thiazide diuretics in the treatment of hypertension in people with diabetes.</li><li>The GDG thought it was sensible to recommend a RAS blocker first line in people with type 1 diabetes, recognizing that:<ul><li>People younger than 55 years account for most adults with type 1 diabetes and hypertension.</li><li>Thiazide diuretics can raise blood glucose levels.</li></ul></li></ul></li></ul><h5>Lipid modification</h5><ul><li>These recommendations are based on the NICE guideline <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016f</a>].</li><li>See the CKS topics on <a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a> and <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for more information.</li></ul><h5>Antiplatelet treatment</h5><ul><li>Low-dose aspirin has been shown to reduce the incidence of CVD in people at high risk for other reasons, particularly if they have had a previous CVD event. However, because its use is associated with an increased risk of bleeding, it is only recommended for the secondary prevention of CVD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>].</li><li>Owing to the high risk of CVD in people with type 1 diabetes, NICE considered the available evidence to assess the effectiveness of antiplatelet treatment for the primary prevention of CVD in this group of people. The GDG was interested in balancing the prevalence of dyspepsia and gastrointestinal bleeding against any reduction in cardiovascular events. </li><li>Based on the available data, there was little robust evidence from the type 1 diabetes population to suggest either benefit or harm from antiplatelet treatment. </li><li>Based on the evidence and on information in the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Aspirin: not licensed for primary prevention of thrombotic vascular disease </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2014a</a>], which suggests that the harms of aspirin for primary prevention outweigh the benefits, NICE does not recommend the use of aspirin for the primary prevention of CVD in people with type 1 diabetes.</li></ul><!-- end field fd381c75-45cd-4d2c-a974-f8a48794c19a --><!-- end item 1a7263e6-d573-4e0d-8e06-132202f7be79 --></div></section></section><section aria-labelledby="monitoring-for-complications" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring-for-complications">How should I monitor for complications in adults with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 24596a5e-c2c1-428f-848d-109a8ab1412a --><!-- begin field 6336088a-300a-42ad-8d61-8e2f5c84c24a --><p><strong>People with type 1 diabetes should have regular surveillance for <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of the disease. The reason for the surveillance as well as the significance of any abnormal findings should be discussed with the person and their family/carers. </strong></p><ul><li><strong>At every review appointment (if clinically indicated):</strong><ul><li>Measure HbA1c to ensure adequate blood glucose control. Reiterate <a class="topic-reference internal-reference" href="index.html#target-hba1c">HbA1c</a> and <a class="topic-reference internal-reference" href="index.html#target-glucose-self-monitoring-levels">glucose self-monitoring</a> targets.</li><li>Measure the person's height, weight, and waist circumference, and calculate their body mass index (BMI). See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for information on managing obesity.</li><li>Assess for depression, anxiety, and eating disorders (including intentional insulin omission in order to lose weight [<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">diabulimia</a>]).<ul><li>Alerting signs of an eating disorder include over-concern with body shape and weight, low BMI, hypoglycaemia, and suboptimal overall blood glucose control.</li><li>See the CKS topics on <a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a>, <a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a>, and <a class="topic-reference external-reference" href="../../../eating-disorders/index.html">Eating disorders</a> for information on managing these conditions.</li></ul></li><li>Check smoking status. If applicable, offer advice on smoking cessation. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a><em><strong> </strong></em>for more information.</li><li>Monitor for neuropathy and associated complications, including erectile dysfunction, neuropathic pain, autonomic neuropathy, and gastroparesis (delayed emptying of the stomach). See the section on <a class="topic-reference internal-reference" href="index.html#neuropathy">Managing neuropathic complications</a> if any neuropathic complications are identified.</li></ul></li><li><strong>Once a year:</strong><ul><li>Check injection sites, and address any injection site problems. See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#managing-injection-site-problems">Managing injection site problems</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for more information.</li><li>Assess for cardiovascular risk factors, including smoking status, waist circumference, blood glucose control, blood pressure, full lipid profile, and family history of cardiovascular disease. See the section on <a class="topic-reference internal-reference" href="index.html#managing-cardiovascular-risk">Managing cardiovascular risk factors</a> for more information.</li><li>Ensure the person is screened for eye disease, kidney disease, and foot problems. See the sections on <a class="topic-reference internal-reference" href="index.html#eye-disease">Eye disease</a>, <a class="topic-reference internal-reference" href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a>, and <a class="topic-reference internal-reference" href="index.html#foot-problems">Diabetic foot problems</a> for more information.</li><li>Ensure the person is screened for thyroid disease. See the CKS topics on <a class="topic-reference external-reference" href="../../../hypothyroidism/index.html">Hypothyroidism</a> and <a class="topic-reference external-reference" href="../../../hyperthyroidism/index.html">Hyperthyroidism</a> for detailed information on screening for (and managing) these conditions.</li></ul></li><li><strong>Be alert for the possibility of the development of other autoimmune diseases, including:</strong><ul><li>Coeliac disease — this should have been screened for at diagnosis.<ul><li>Assess for coeliac disease if the person has a low BMI or unexplained weight loss. See the CKS topic on <a class="topic-reference external-reference" href="../../../../coeliac-disease.html">Coeliac disease</a> for more information.</li></ul></li><li>Addison’s disease. See the section on <a class="topic-reference external-reference" href="../../../addisons-disease/diagnosis/index.html">Diagnosis</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../addisons-disease/index.html">Addison's disease</a> for information on the clinical features of Addison's disease.</li><li>Pernicious anaemia. See the section on <a class="topic-reference external-reference" href="../../../anaemia-b12-folate-deficiency/diagnosis/index.html">Diagnosis</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../anaemia-b12-folate-deficiency/index.html">Anaemia - B12 and folate deficiency</a><em><strong> </strong></em>for information on the clinical features of pernicious anaemia.</li></ul></li></ul><!-- end field 6336088a-300a-42ad-8d61-8e2f5c84c24a --><!-- end item 24596a5e-c2c1-428f-848d-109a8ab1412a --></div><section aria-labelledby="eye-disease" class="ChapterBody-module--wrapper--2HCfk "><h4 id="eye-disease">Screening for eye disease</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c8e47d2b-6a77-4ff4-ba29-aebf18027726 --><!-- begin field 7cc32cf7-51a5-414c-a652-b4511eabee8a --><ul><li><strong>On diagnosis, immediately refer adults with type 1 diabetes to the local eye screening service.</strong><ul><li>Perform screening as soon as possible and no later than 3 months from referral.</li><li>Arrange repeat structured eye screening annually.</li></ul></li><li><strong>Depending on the findings, follow structured eye screening by one of the following: </strong><ul><li>Referral to an ophthalmologist.</li><li>Earlier review.</li><li>Routine annual review.<ul><li>The <a href="https://www.gov.uk/guidance/diabetic-eye-screening-programme-overview" data-hyperlink-id="4795bc76-4502-4640-bd48-abc80070f2d3">NHS diabetic eye screening</a> (DES) is offered once a year to anyone with diabetes who is aged 12 years or over. </li><li>The programme aims to reduce the risk of sight loss among people with diabetes by the early detection and treatment, if needed, of sight-threatening retinopathy.<strong> </strong></li></ul></li></ul></li><li><strong>Explain the reasons and success of eye screening systems to the person and their family/carers </strong>so that attendance is not reduced by lack of knowledge or fear of outcome.</li><li><strong>Arrange:</strong><ul><li><strong>Emergency opthalmology review if there is:</strong> <ul><li>Sudden loss of vision. </li><li>Rubeosis iridis (formation of abnormal blood vessels on the anterior iris). </li><li>Pre-retinal or vitreous haemorrhage. </li><li>Retinal detachment. </li></ul></li><li><strong>Urgent opthalmology review if there is:</strong><ul><li>Formation of new abnormal vessels on the retina. </li></ul></li></ul></li></ul><!-- end field 7cc32cf7-51a5-414c-a652-b4511eabee8a --><!-- end item c8e47d2b-6a77-4ff4-ba29-aebf18027726 --></div></section><section aria-labelledby="diabetic-kidney-disease" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diabetic-kidney-disease">Diabetic kidney disease</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0268779a-8dbc-4135-b5b0-1ae7b750d988 --><!-- begin field c563a0d9-23f4-4f9e-866c-42c27dbceab6 --><ul><li><strong>All adults with type 1 diabetes (with or without detected nephropathy) should receive annual screening for diabetic nephropathy. </strong><ul><li><strong>Ask the person to bring in the first urine sample of the day ('early morning urine') once a year.</strong><ul><li>Send the urine specimen for estimation of the albumin:creatinine ratio (ACR). </li><li>Check serum creatinine at the same time to calculate estimated glomerular filtration rate (eGFR).</li></ul></li><li><strong>Diagnose chronic kidney disease (CKD)</strong> if the person's eGFR is persistently less than 60 mL per minute per 1.73 m² and/or ACR is persistently greater than 3 mg/mmol.<ul><li>See the section on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/diagnosis/index.html">Diagnosis</a><em> </em>in the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information on diagnosing CKD. </li></ul></li><li><strong>Suspect other renal disease:</strong><ul><li>In the absence of progressive retinopathy.</li><li>If blood pressure is particularly high.</li><li>If proteinuria develops suddenly.</li><li>If the person is systemically unwell.</li><li>If significant persistent non-visible haematuria is present (that is, two out of three dipstick tests show 1+ or more of blood after exclusion of a urinary tract infection).</li></ul></li></ul></li><li><strong>For adults with type 1 diabetes who have confirmed nephropathy, including those with moderately increased albuminuria (microalbuminuria) alone:</strong><ul><li>Consider whether referral to a nephrology specialist is indicated, for example if the person has an eGFR of less than 30 mL per minute per 1.73 m<sup>2</sup>. See the section on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/management/management-of-chronic-kidney-disease/index.html#referral">Referral</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for information on when to arrange referral to a nephrology specialist.</li><li>Offer an angiotensin-converting enzyme (ACE) inhibitor provided there are no contraindications. If ACE inhibitors are contraindicated or not tolerated, offer an angiotensin-II receptor antagonist (AIIRA) if appropriate.<ul><li>Start with a low dose and titrate up to the maximum tolerated therapeutic dose (within the maximum licensed dose), by doubling the dose every 1–2 weeks. After each upward titration, monitor the person's renal function, serum potassium level, and blood pressure.</li><li>Do not offer a combination of an ACE inhibitor and an AIIRA.</li><li>See the section on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/prescribing-information/index.html">Prescribing information</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for detailed information on prescribing an ACE inhibitor or AIIRA.</li></ul></li><li>Aim to maintain the systolic blood pressure below 130 mmHg (target range 120–129 mmHg) and the diastolic blood pressure below 80 mmHg.<ul><li>It may be necessary to prescribe additional antihypertensive drugs to control blood pressure adequately.</li></ul></li><li>Advise the person to avoid a high protein diet. Consider referring the person to a dietitian or the specialist diabetes team for dietary advice.</li><li>Offer lipid modification therapy (without the need for a formal risk assessment). See the CKS topic on <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for more information.</li><li>See the section on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/management/management-of-chronic-kidney-disease/index.html#management-in-primary-care">Primary care management</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for further management information.</li></ul></li></ul><!-- end field c563a0d9-23f4-4f9e-866c-42c27dbceab6 --><!-- end item 0268779a-8dbc-4135-b5b0-1ae7b750d988 --></div></section><section aria-labelledby="neuropathy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="neuropathy">Neuropathy</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 30a699f2-0dbe-4d3f-978a-abc3006b21bf --><!-- begin field b290d21f-2434-410b-ae64-abc3006b5962 --><h5>Chronic painful neuropathy</h5><ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../neuropathic-pain-drug-treatment/index.html">Neuropathic pain - drug treatment</a> for information on drug treatments for neuropathic pain.</li></ul><h5>Erectile dysfunction</h5><ul><li>Offer men the opportunity to discuss erectile dysfunction as part of their regular review.</li><li>Offer a phosphodiesterase-5 (PDE-5) inhibitor (sildenafil, vardenafil, or tadalafil) to men with type 1 diabetes with isolated erectile dysfunction, unless contraindicated. Choose the PDE-5 inhibitor with the lowest acquisition cost. See the section on <a class="topic-reference external-reference" href="../../../erectile-dysfunction/prescribing-information/index.html">Prescribing information</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../erectile-dysfunction/index.html">Erectile dysfunction</a> for detailed information on prescribing PDE-5 inhibitors, including contraindications and cautions.</li><li>If PDE-5 inhibitor treatment is contraindicated or unsuccessful, consider referring the man to a service offering further assessment and other medical, surgical, or psychological management of erectile dysfunction.</li></ul><h5>Autonomic neuropathy</h5><ul><li>For adults with unexplained diarrhoea, particularly at night, consider (and investigate) the possibility of autonomic neuropathy affecting the gut.</li><li>For adults with bladder emptying problems, consider (and investigate) the possibility of autonomic neuropathy affecting the bladder, provided alternative causes (for example lower urinary tract problems) have been excluded. See the CKS topics on <a class="topic-reference external-reference" href="../../../luts-in-men/index.html">LUTS in men</a>, <a class="topic-reference external-reference" href="../../../urinary-tract-infection-lower-men/index.html">Urinary tract infection (lower) - men</a>, and <a class="topic-reference external-reference" href="../../../urinary-tract-infection-lower-women/index.html">Urinary tract infection (lower) - women</a> for more information on managing these conditions.</li><li>For adults with vomiting caused by gastroparesis:<ul><li>Advise a small-particle-size diet (mashed or pureed food) for symptomatic relief. </li><li>Consider referral to a gastroenterologist or the diabetes specialist team for consideration of treatment with a prokinetic drug, such as erythromycin (off-label use), metoclopramide, or domperidone.</li><li>Continuous subcutaneous insulin infusion (CSII or insulin pump) therapy may be considered in secondary care if there are ongoing symptoms. <ul><li>If symptoms persist despite insulin pump therapy, further specialist referral is likely to be needed.</li><li>See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#recommended-insulin-regimen">Recommended insulin regimen</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for information on insulin pump therapy.</li></ul></li></ul></li><li>For adults with excessive sweating, see the CKS topic on <a class="topic-reference external-reference" href="../../../hyperhidrosis/index.html">Hyperhidrosis</a>.</li><li>For adults taking antihypertensive drugs, be aware of the increased risks of postural hypotension as a result of the combined effects of sympathetic autonomic neuropathy and antihypertensive drug treatment.</li></ul><h5>Acute painful neuropathy of rapid improvement of blood glucose control</h5><ul><li>Reassure the person that acute painful neuropathy resulting from rapid improvement of blood glucose control is a self-limiting condition that improves symptomatically over time.</li><li>Explain that the specific treatments for this condition:<ul><li>Aim to make the symptoms tolerable until the condition resolves.</li><li>May not relieve pain immediately and may need to be taken regularly for several weeks to be effective.</li></ul></li><li>Advise the use of simple analgesics (paracetamol or a nonsteroidal anti-inflammatory drug [NSAID]) and local measures (such as a bed cradle — a frame that attaches to the bed to keep sheets and blankets from touching and rubbing the body) to relieve symptoms. <ul><li>If simple analgesics are ineffective, offer treatment as described in the CKS topic on <a class="topic-reference external-reference" href="../../../neuropathic-pain-drug-treatment/index.html">Neuropathic pain - drug treatment</a>. </li><li>Simple analgesia may be continued until the effects of additional treatments have been established.</li><li>The use of weak opioids is not recommended owing to the risk of dependency associated with their use.</li></ul></li><li>Do not relax blood glucose diabetes control if this condition is identified.</li></ul><!-- end field b290d21f-2434-410b-ae64-abc3006b5962 --><!-- end item 30a699f2-0dbe-4d3f-978a-abc3006b21bf --></div></section><section aria-labelledby="foot-problems" class="ChapterBody-module--wrapper--2HCfk "><h4 id="foot-problems">Screening for diabetic foot problems</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item de0897a6-3b39-4f25-a4e1-b7c138ff3aad --><!-- begin field 43952da5-5dc1-426d-9d6a-f1f1cfc9c059 --><p><strong>P</strong><strong>eople with type 1 diabetes should have their feet checked by a primary healthcare professional at diagnosis and at least once a year thereafter, or sooner if any foot problems arise. </strong><strong>They should also be advised to check their own feet on a daily basis.</strong></p><ul><li><strong>To examine the feet of a person with diabetes, remove t</strong><strong>heir shoes, socks, bandages, and dressings (as appropriate) and examine both feet for evidence of the following risk factors:</strong><ul><li>Neuropathy — use a 10 g monofilament as part of a foot sensory examination. </li><li>Limb ischaemia — use ankle brachial pressure index (ABPI) and interpret results carefully because calcified arteries may falsely elevate results. See the CKS topic on <a class="topic-reference external-reference" href="../../../peripheral-arterial-disease/index.html">Peripheral arterial disease</a> for more information.</li><li>Ulceration.</li><li>Callus formation.</li><li>Infection and/or inflammation.</li><li>Deformity.</li><li>Gangrene.</li><li>Charcot arthropathy (an acute, localized inflammatory condition that may lead to varying degrees and patterns of bone destruction, subluxation, dislocation, and deformity).</li></ul></li><li><strong>Assess the person's current risk of developing a diabetic foot problem or needing an amputation using the following risk stratification:</strong><ul><li>Low risk:<ul><li>No risk factors present except callus alone.</li></ul></li><li>Moderate risk:<ul><li>Deformity, <em>or</em></li><li>Neuropathy, <em>or </em></li><li>Non-critical limb ischaemia.</li></ul></li><li>High risk:<ul><li>Previous ulceration, <em>or</em></li><li>Previous amputation, <em>or</em></li><li>On renal replacement therapy, <em>or</em></li><li>Neuropathy and non-critical limb ischaemia together, <em>or</em></li><li>Neuropathy in combination with callus and/or deformity,<em> or </em></li><li>Non-critical limb ischaemia in combination with callus and/or deformity. </li></ul></li><li>Active diabetic foot problem:<ul><li>Ulceration, <em>or</em></li><li>Spreading infection, <em>or</em></li><li>Critical limb ischaemia, <em>or</em></li><li>Gangrene, <em>or </em></li><li>Suspicion of an acute Charcot arthropathy, or an unexplained hot, red, swollen foot with or without pain. </li></ul></li></ul></li><li><strong>Manage the person's </strong><strong>risk of developing a diabetic foot problem.</strong><ul><li>For people who are at low risk of developing a diabetic foot problem, continue to carry out annual foot assessments, emphasize the importance of foot care, and advise that they could progress to moderate or high risk.</li><li>For people at moderate or high risk of developing a diabetic foot problem, refer to the foot protection service. They should be seen within 2–4 weeks if at high risk or within 6–8 weeks if at moderate risk.</li><li>For people with a limb-threatening or life-threatening diabetic foot problem, refer immediately to acute services, and inform the multidisciplinary foot care service (according to local protocols and pathways) so that they can be assessed and an individualized treatment plan put in place. Examples of limb-threatening and life-threatening diabetic foot problems include:<ul><li>Ulceration with fever or any signs of sepsis.</li><li>Ulceration with limb ischaemia.</li><li>Clinical concern that there is a deep-seated soft tissue or bone infection (with or without ulceration).</li><li>Gangrene (with or without ulceration).</li></ul></li><li>For all other active diabetic foot problems, refer the person within 1 working day to the multidisciplinary foot care service or foot protection service (according to local protocols and pathways) for triage within 1 further working day. </li></ul></li><li><strong>Depending on the person's risk of developing a diabetic foot problem, carry out reassessments at the following intervals:</strong><ul><li>Annually — for people who are at low risk.</li><li>Frequently (for example every 3–6 months) — for people who are at moderate risk. </li><li>More frequently (for example every 1–2 months) — for people who are at high risk, if there is no immediate concern. More frequent reassessments should be considered for people who are unable to check their own feet.</li><li>Very frequently (for example every 1–2 weeks) — for people who are at high risk, if there is immediate concern. </li></ul></li><li><strong>Provide appropriate information on </strong><strong>the risk of developing a diabetic foot problem to all people with type 1 diabetes.</strong> This information should be provided at diagnosis, during assessments, and if foot problems arise, and should include the following:<ul><li>Basic foot care advice and the importance of foot care.</li><li>Foot emergencies and who to contact.</li><li>Footwear advice.</li><li>The person's current individual risk of developing a foot problem.</li><li>Information on diabetes and the importance of blood glucose control.</li></ul></li><li><strong>If a person presents with a diabetic foot problem, take into account that they may have an undiagnosed, increased risk of cardiovascular disease (CVD) that may need further investigation and treatment. </strong>See the CKS topics on <a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a> and <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for more information on the investigation and treatment of CVD.</li></ul><!-- end field 43952da5-5dc1-426d-9d6a-f1f1cfc9c059 --><!-- end item de0897a6-3b39-4f25-a4e1-b7c138ff3aad --></div></section><section aria-labelledby="basis-for-recommendation-6fa" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-6fa">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6fad5025-8065-4bad-969b-edf99c280f38 --><!-- begin field 56a83ce5-46cd-4eef-9054-ef214b863adb --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng17/evidence/full-guideline-pdf-435400241" data-hyperlink-id="0da19505-b35e-4c8a-9c90-a93100987082">full NICE guideline</a>.</p><h5>Regular monitoring for complications and associated conditions</h5><ul><li>Expert opinion in the NICE guideline is that people with type 1 diabetes need regular monitoring for signs of complications and for the factors that increase their individual risk of developing these<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>]. Based on their assessed needs, they should be offered appropriate interventions and/or referral in order to reduce the progression of late complications into adverse health outcomes.</li></ul><h5>Eye disease</h5><ul><li>CKS has not outlined the individual NICE recommendations regarding screening for eye disease in people with type 1 diabetes because this is usually done as part of the annual <a href="https://www.gov.uk/guidance/diabetic-eye-screening-programme-overview" data-hyperlink-id="e641f35e-8e71-488a-8623-abc80071381c">NHS diabetic eye screening (DES) programme</a>. However, information on the need for an emergency review or urgent review by an ophthalmologist has been highlighted as these people may be seen in primary care.</li></ul><h5>Diabetic kidney disease</h5><ul><li>The NICE guideline development group (GDG) refers to the NICE guideline on <a href="https://www.nice.org.uk/guidance/cg182/chapter/introduction" data-hyperlink-id="6a9343f7-f8eb-4e4f-bebe-ac00009401aa">Chronic kidney disease</a> for recommendations on managing kidney disease in adults with type 1 diabetes. <ul><li>Proteinuria is a cardinal sign of kidney damage, and it can be quantified by measuring the albumin:creatinine ratio (ACR) [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]:<ul><li>An ACR level of 3 mg/mmol is more than 3 times the normal value for young men and women; therefore, people with an ACR of greater than 3 mg/mmol should be considered to be at greater risk of cardiovascular disease (CVD), mortality, and adverse renal outcomes regardless of the estimated glomerular filtration rate (eGFR).</li><li>Significant proteinuria is an independent risk factor for progression of CKD and is associated with a doubling of cardiovascular risk and mortality at all levels of GFR. </li><li>A morning urine sample is more reliable as false-positive proteinuria (due to the presence of orthostatic proteinuria, which is not clinically significant) is less likely to be detected.</li></ul></li><li>Serum creatinine is an endogenous test of kidney function; as kidney disease progresses, serum creatinine level increases [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]:<ul><li>GFR is the best overall measure of kidney function, and serum creatinine levels can be used to calculate eGFR.</li><li>An eGFR of 125 mL per minute per 1.73 m<sup>2</sup> is the normal value for young adult men and women. </li><li>An eGFR of less than 60 mL per minute per 1.73 m<sup>2</sup> is associated with a higher risk for complications of CKD.</li></ul></li></ul></li></ul><h5>Neuropathy</h5><ul><li><strong>Managing chronic painful neuropathy</strong><ul><li>The NICE GDG refers to the NICE guideline on <a href="http://www.nice.org.uk/guidance/cg173" data-hyperlink-id="4ded53f9-d18f-4876-8f25-ac0000940206">Neuropathic pain – pharmacological management</a> for information on managing people with chronic painful neuropathy.</li></ul></li><li><strong>Managing erectile dysfunction</strong><ul><li>NICE reviewed the available evidence to determine whether pharmacological treatments (phosphodiesterase-5 inhibitors, testosterone therapy, and alprostadil) should be used in the management of erectile dysfunction in men with diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>].<ul><li>Very low- to low-quality clinical evidence showed that erectile function was significantly improved with the use of phosphodiesterase-5 inhibitors compared with placebo. A subsequent review of the evidence showed no significant difference in outcome achieved for measures of erectile function using sildenafil, vardenafil, or tadalafil. One small study (n = 219) in men with type 2 diabetes reported a significantly improved quality of life score with sildenafil compared with placebo (moderate-quality evidence).</li><li>A cost-effectiveness analysis reported that sildenafil and vardenafil were cost effective compared with placebo or alternative treatments. Although none of the studies were specific to men with diabetes, the GDG accepted that it was possible to extrapolate findings from these studies to populations with diabetes. </li><li>The GDG was unable to make any recommendations on the use of testosterone and alprostadil for this indication owing to the lack of good-quality evidence.</li></ul></li></ul></li><li><strong>Managing gastroparesis</strong><ul><li>NICE reviewed the available evidence to determine the impact of different interventions on the symptoms and clinical outcomes of gastroparesis<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>].<ul><li>Erythromycin increased gastric motility, but a significant reduction in symptom severity scores was not achieved in trials.</li><li>Metoclopramide reduced physical symptoms and vomiting. </li><li>Domperidone reduced physical symptoms and vomiting but had no effect on the psychological impact associated with gastroparesis.</li></ul></li><li>NICE noted the Medicines and Healthcare products Regulatory Agency (MHRA) warning on the use of metoclopramide and domperidone, but considered that the risks associated with these treatments had to be weighed carefully against the risks and distress caused by uncontrolled chronic causes of vomiting, such as diabetic gastroparesis. <ul><li>Metoclopramide has well-known risks of neurological effects, such as short-term extrapyramidal disorders and tardive dyskinesia; therefore, it should be prescribed for short-term use only (up to 5 days) and at a maximum daily dose of 30 mg (usual dose of 10 mg up to three times a day) [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2014b</a>].</li><li>Domperidone is associated with a small increased risk of serious cardiac adverse effects (such as ventricular arrhythmias, QT interval prolongation, and sudden cardiac death), especially in people older than 60 years of age, people taking daily oral domperidone doses of more than 30 mg, and people taking QT-prolonging drugs (such as erythromycin) or cytochrome P450 3A4 inhibitors at the same time as domperidone [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2014c</a>].</li></ul></li><li>NICE does not make any recommendations on the dose of prokinetic drug to be prescribed or the duration of treatment, but recommends an alternating treatment of erythromycin and metoclopramide. CKS recommends seeking specialist advice if considering a prokinetic drug for an adult with vomiting caused by gastroparesis. </li></ul></li><li><strong>Managing acute neuropathy from rapid improvement of blood glucose control</strong><ul><li>NICE reviewed the available evidence to<strong> </strong>determine the optimum treatment for acute painful neuropathy from rapid improvement of blood glucose control in people with type 1 diabetes<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>].<ul><li>The evidence for antidepressants (including tricyclic antidepressants and duloxetine), anti-epileptic treatments (including gabapentin and pregabalin), and analgesia (including opiates) did not show any treatment to be better than another in the management of this condition. No evidence was found for topical anaesthetics, capsaicin cream, and insulin pump therapy.</li><li>The NICE GDG recognized that acute painful neuropathy of rapid blood glucose control is an uncommon condition that is likely to resolve spontaneously, even without treatment. However, they acknowledged that people with this condition subjectively report intense pain; therefore, clinical interventions aimed at reducing the intensity of the pain are warranted.</li><li>The GDG recommends simple analgesia first line, then treatment as described in the NICE guideline <em>Neuropathic pain - pharmacological management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019c</a>] if simple analgesics are ineffective. </li><li>The GDG warned about the risk of dependence with opioids and stressed that alternative treatments should be used, especially since there is no evidence that opioids are more effective than other therapeutic interventions in providing symptomatic relief for this condition.</li></ul></li></ul></li></ul><h5>Foot care</h5><ul><li>The recommendations on foot care are based on the NICE guideline <em>Diabetic foot problems: prevention and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>]. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng19/evidence/full-guideline--august-2015-pdf-15672915543" data-hyperlink-id="6ffe0b4b-f81e-4e51-8b4e-a931009895cc">full NICE guideline</a> on diabetic foot problems.</li><li>The definition of Charcot arthropathy is taken from a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Rogers, 2011</a>].</li></ul><h5>Being alert to the development of other autoimmune diseases</h5><ul><li>NICE advises that healthcare professionals should be alert to the development of other autoimmune diseases in people with type 1 diabetes<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>].<ul><li>The most common autoimmune conditions associated with type 1 diabetes are thyroid disease (Graves' disease or Hashimoto's thyroiditis, 15–30%), autoimmune gastritis and/or pernicious anaemia (5–10%), coeliac disease (4–9%), vitiligo (2–10%), and Addison’s disease (0.5%) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Van den Driessche, 2009</a>].</li><li>The NICE guideline on <em>Coeliac disease: recognition, assessment and management </em>states that people with type 1 diabetes should be offered serological testing for coeliac disease at diagnosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015c</a>].</li></ul></li></ul><!-- end field 56a83ce5-46cd-4eef-9054-ef214b863adb --><!-- end item 6fad5025-8065-4bad-969b-edf99c280f38 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/diabetes-type-1/management/management-adults/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>